Skip to main content

Macromolecular prodrug-based therapy for indolent neuroblastoma

Michael Chorny, PhD

Children’s Hospital of Philadelphia

Neuroblastoma is the most common and deadly solid tumor in children. Although less than 10% of neuroblastomas are diagnosed in older children and adolescents, these patients are particularly difficult to treat, resulting in a long-term survival rate of less than 5%. Dr. Michael Chorny, a Research Associate Professor of Pediatrics at the Children’s Hospital of Philadelphia, has developed a novel, polymer-linked drug precursor (or prodrug) which is slowly converted in the patient’s bloodstream to an active anticancer agent. With grant funds provided by CURE Childhood Cancer, Dr. Chorny will perform the necessary work in preclinical models to prepare for FDA-approved testing in children. If successful, this novel agent may provide an important therapeutic advance for older children with neuroblastoma.